Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024

Rhea-AI Summary

Lexicon Pharmaceuticals (Nasdaq: LXRX) has announced its upcoming third quarter 2024 financial results conference call and webcast, scheduled for November 12, 2024, after market close. The management will host a conference call and live webcast at 5:00 p.m. ET to discuss financial results and provide a business update. The event will be accessible via phone and webcast, with replay options available for 7 days via phone and 14 days via webcast on the company's website.

THE WOODLANDS, Texas, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its third quarter 2024 financial results on Tuesday, November 12, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update.

Dial-in Information
U.S. Dial-in Number: (888) 317-6003
International Dial-in Number: (412) 317-6061
Conference ID: 1004487

Replay Information
U.S. Dial-in Number: (877) 344-7529
Replay International Dial-in Number: (412) 317-0088
Conference ID: 7374787

The dial-in replay will be available for 7 days following the call. An audio webcast will be available online at www.lexpharma.com/events, with a webcast replay accessible for 14 days after the call.

About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat disease safely and effectively. Lexicon has commercially launched one of these medicines, INPEFA® (sotagliflozin) in the United States, and has a pipeline of other promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, conduct preclinical and clinical development, obtain necessary regulatory approvals of  and successfully commercialize sotagliflozin , LX9211, LX9851 and its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2023 and other subsequent disclosure documents filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.  

For Investor and Media Inquiries: 
Lisa DeFrancesco  
Lexicon Pharmaceuticals, Inc.         
lexinvest@lexpharma.com 

FAQ

When will Lexicon Pharmaceuticals (LXRX) release Q3 2024 earnings?

Lexicon Pharmaceuticals will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after the markets close.

How can I access LXRX's Q3 2024 earnings call?

You can access the call via phone (U.S.: 888-317-6003, International: 412-317-6061, Conference ID: 1004487) or through the webcast at www.lexpharma.com/events at 5:00 p.m. ET on November 12, 2024.

How long will LXRX's Q3 2024 earnings call replay be available?

The phone replay will be available for 7 days following the call, while the webcast replay will be accessible for 14 days after the call.